Biohaven also announces new clinical supply agreement with Regeneron to evaluate BHV-1530 in combination with cemiplimab (Libtayo®)
NEW HAVEN, Conn. , July 9, 2026 /PRNewswire/ --Â Biohaven Ltd. (NYSE: BHVN) ("Biohaven" or the "Company") today announced scientific leadership role transitions designed to accelerate drug innovation...
NEW HAVEN, Conn. , June 30, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing...
The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.18%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.59%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +2.25%. September E-mini...
The S&P 500 Index ($SPX ) (SPY ) is up +0.73% today; the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.08%. September E-mini S&P futures...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.59%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.64%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.67%. September E-mini S&P futures...
NEW HAVEN, Conn. , June 29, 2026 /PRNewswire/ --Â Biohaven Ltd. (NYSE: BHVN) today announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves' disease. BHV-1300...
NEW HAVEN, Conn. , June 1, 2026 /PRNewswire/ --Â Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...
NEW HAVEN, Conn. , May 27, 2026 /PRNewswire/ --Â Biohaven Ltd. (NYSE: BHVN) ("Biohaven") a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
NEW HAVEN, Conn. , May 26, 2026 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing...